Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

@article{Marenco2002PreliminaryEW,
  title={Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series},
  author={Stefano Marenco and Michael F. Egan and Terry E. Goldberg and Michael B. Knable and Daniel R. Weinberger},
  journal={Schizophrenia Research},
  year={2002},
  volume={57},
  pages={221-226}
}
We used L-(quinoxalin-6-ylcarbonyl)piperidine (CX516) (a modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid (AMPA) receptor) as a sole agent in a double blind placebo-controlled design in a small series of patients with schizophrenia who were partially refractory to treatment with traditional neuroleptics. The study entailed weekly increments in doses of CX516, from 300 mg tid for week 1 up to 900 mg tid on week 4. Patients were followed with clinical ratings… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

NEUROANALYST NeuroAnalysis Second Edition

D. AbrahamPeledM., Abraham Peled
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Update on New and Emerging Treatments for Schizophrenia.

  • The Psychiatric clinics of North America
  • 2016
VIEW 1 EXCERPT
CITES RESULTS

Das vergessene Transmittersystem

VIEW 1 EXCERPT
CITES BACKGROUND